Skip to main content

The effect of omega3 fatty acid supplementation on PPARγ and UCP2 expressions, resting energy expenditure, and appetite in athletes



Omega3 fatty acids as a ligand of energy-related genes, have a role in metabolism, and energy expenditure. These effects are due to changes in the expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and uncoupling protein2 (UCP2). This study evaluated the effect of omega3 supplements on PPARγ mRNA expression and UCP2 mRNA expression and protein levels, as regulators of energy metabolism, resting energy expenditure (REE), and appetite in athletes.


In a 3-week double-blind RCT in Tabriz, Iran, in 2019, 36 male athletes, age 21.86 (±3.15) y with 16.17 (±5.96)% body fat were randomized to either an intervention (2000 mg/day omega3; EPA: 360, DHA: 240) or placebo (2000 mg/day edible paraffin) groups. Appetite and REE were assessed before and after the intervention. PPARγ and UCP2 mRNA expression and UCP2 protein levels in blood were evaluated by standard methods.


Results showed PPARγ mRNA levels, and UCP2 mRNA and protein levels increased in omega3 group (p < 0.05), as did REE (p < 0.05). Also, differences in the sensation of hunger or satiety were significant (p < 0.05).


Our findings showed that omega3 supplementation leads to the up-regulation of PPARγ and UCP2 expressions as the indicators of metabolism in healthy athletes.

Peer Review reports


Body composition is important for athletes in various types of sports because performance is affected by the ratio of fat mass (FM) and fat-free mass (FFM) [1,2,3]. For many athletes reducing body fat, it is associated with improved performance, such as material arts, and handball [4, 5]. Although, many factors change body composition, most of these factors are related to the body’s metabolism [6, 7]. Nutrition and physical activity are important lifestyle factors that affect metabolic markers associated with energy metabolism [8]. Studies showed nutrients such as omega3 fatty acids have potential to reduce FM accumulation particularly visceral fat [9,10,11,12,13,14,15,16,17]. The effect of omega3 fatty acids on weight (fat) reduction is due to increased fat oxidation, and energy expenditure [10]. Omega3 alters multiple signaling pathways, including those related to p21, p53, nuclear f4ractor κB, and STAT [18, 19].

Omega3s, which are essential for humans, mainly include eicosapentaenoic acid (EPA; 20:5), and docosahexaenoic acid (DHA; 22:6) from marine foods and supplements [20,21,22,23,24,25]. It is recommended that adults consume 500 mg/day of EPA and DHA by two servings of oily fish such as salmon, herring, and mackerel per week [26]. But the intake of omega3 from foods contributes to the provision of only a small amount of daily requirements [27]. Thus, the American Heart Association recommends if the adults do not consume enough fish, they should consume omega3 supplements [13].

On the other hand, omega3 could act as a ligand for peroxisome proliferator-activated receptor gamma (PPARγ) [8, 28]. PPARγ is a steroid nuclear transcription factor that regulates the expression of many genes to modulate energy metabolism, cell differentiation, and apoptosis [29,30,31].. PPARγ is mainly expressed in adipose tissue and is directly related to adipocytes [32]. An animal study showed omega3 fatty acids decrease fat in adipose tissue through the expression of PPARγ [30]. However, few studies on humans have been conducted. Although, the results of these studies imply that PPARγ gene expression partially controlled by nutritional regulation [10, 30]. PPARγ activates the expression of other genes involved in energy metabolism, such as uncoupling protein 2 (UCP2). UCP2 is located in the inner mitochondrial membrane and promotes leakage of protons. Changes in the proton gradient affects ATP production. The expression of the UCP2 decreased in cardiovascular diseases [33,34,35,36]. But the effect of omega3 supplementation on UCP2 mRNA expression and UCP2 protein is controversial [37,38,39,40].

Interestingly, UCP2 up-regulates PPARγ expression, and their effect on metabolism may be synergistic [41, 42]. As the PPARγ and UCP2 genes expression are increased, the production of various hormones and neurotransmitters are enhanced. This process increases the proteins that affect metabolism, and resting energy expenditure. Also, changes in the expression of these genes could change blood lipids, fat mass, and appetite [43,44,45,46]. For example, increasing PPARγ expression suppresses ghrelin and thus reduces appetite [47]. Another study showed UCP2 suppresses appetite by modulating ghrelin expression [48]. As a change in appetite could alter the food intake, it might affect fat accumulation and metabolism [47, 49].

So far no study has directly examined the relationship between omega3 supplementation, expression of metabolism-related genes, and mitochondrial proteins. Considering that maintenance of optimal body composition is important for many athletes, this study aimed to determine the effect of omega3 supplementation on the expression of the PPARγ, UCP2, and the concentration of UCP2 protein in the blood, resting energy expenditure, and appetite in healthy athletes.


Subjects and study design

This was a randomized double-blind placebo-controlled trial involving 36 athlete men. The duration of the project was three weeks. Following a public announcement of the study, volunteers who willing to participate were recruited from public and private gyms, teams, stadiums, councils, and departments of sports, departments of physical education, and the sports medicine board in Tabriz, Iran. After being given a full explanation of the study procedures, participants who agreed to enroll in the study signed a statement of informed consent before the commencement of baseline data collection. The study procedure and the informed consent form were approved by the ethics committee of the medical university of Tabriz (IR.TBZMED.REC.1398.782) in October 2019, and the procedures were performed in accordance with relevant guidelines. The trial was registered at the Iranian registry of the clinical trial website ( as IRCT20190625044008N1 (, registered at (19/12/2019).

Inclusion/exclusion criteria

The inclusion criteria were: 1) athlete volunteers who were ranked nationally or players of a professional sports league (football, volleyball, swimming, etc.); 2) age range of 20 to 30 years; 3) BMI between 18.5 to 25 kg/m2; 4) avoidance of any dietary supplements, vitamins, minerals, and protein powders at least six months before and throughout the intervention; 5) Not having a history of coagulopathy blood disease, liver damage, kidney disease, pancreatitis, inflammatory diseases, diabetes, cancer, thyroid disorders,, and heart disease; 6) not smoking. The exclusion criteria were: 1) allergic response to the omega3; 2) unwillingness for cooperation; 3) any major change in diet, duration, level, or type of physical activity and regular lifestyle;

Sample size

The sample size was estimated by considering the expected differences (d) between the two studied groups for one of the main outcomes (REE was used from a previous clinical trial [44]). We calculated the sample size as follows: d = 3.77 Z1-α/2 = 1.96 α = 0.05 1-β = 0.90 Z1-β = 1.282

$$ \mathrm{n}=\raisebox{1ex}{$\left({\left(\left(z1-\frac{\alpha }{2}\right)\left(z1-\beta \right)\right)}^2\ast {\left( SD1+ SD2\right)}^2\right)$}\!\left/ \!\raisebox{-1ex}{${(d)}^2$}\right. $$

According to the equation above, the sample size was calculated as 14 in each group and we selected 18 in each group, to account for a possible 30% loss to follow-up or discontinued intervention.

Randomization, blinding, and study procedures

Participants who met the eligibility criteria were randomly assigned to the omega3 (n = 18) and placebo (n = 18) groups. For randomization, a blinded colleague who was not involved in any of the study stages randomly divided the participants into the intervention and placebo groups (1:1) by using RAS (Random Allocation Software). Omega 3 or placebo containers with identical labeling and they were similar in terms of color, shape, and size. Gelatin capsule supplements and placebo were stored at room temperature. The adequate intake of omega3 for men between the ages of 19–50 years is 1600 mg per day. In similar previous studies, the dose of omega3 supplementation ranged from 200 mg to 6 g per day, and by considering the low amount of omega3 in of the Iranian diet, an effective dose at 2 g per day was intended for this study [50,51,52,53]. Participants were stratified into two groups:

  1. 1)

    The Omega 3 group receiving supplements of two Omega 3 soft gel capsules per day (Zahravi Pharmaceutical Co, Tabriz, Iran, consists of 240 mg of DHA, 360 mg EPA).

  2. 2)

    The placebo group receiving placebo two soft gel capsules per day, each capsule containing one g of edible paraffin oil (provided by Zahravi Pharmaceutical, Co., Tabriz, Iran).

Participants were asked to return bottles of supplement and the compliance of participants was evaluated by counting the number of unconsumed capsules at the end of the intervention. None of the participants who completed the trial had compliance less than 90%; therefore, no participants were excluded for inadequate compliance. Participants were advised to maintain their regular diet and level of physical activity during the study. Participants were contacted weekly to track any problems or adverse events, reminded to take their supplements, and to evaluate whether diet or physical activity had changed. None of the participants were excluded because of substantial changes in diet or physical activity. Adverse events were also tracked for a week after the end of the intervention.

Assessment of physical activity

Physical activity levels were estimated with the global physical activity questionnaire (GPAQ) [54]. A trained researcher filled out the questionnaire for each participant via face-to-face interview. The validity and reliability of the GPAQ have been previously confirmed [55]. Data were processed according to guidelines for analysis of the GPAQ and total metabolic equivalents score (MET-minutes/week) was calculated, with participants categorized as high (≥3000 METs), moderate and low (< 3000 METs) levels of activity.

Assessment of appetite

A 10 cm visual analog scale (VAS) questionnaire (with six items: hunger, satisfaction, desire to eat, desire to eat sweet, desire to eat salty, desire to eat fatty) were completed in the morning after fasting and after giving blood samples. The validity and reliability of this questionnaire were previously reported [50].

Anthropometric and blood pressure measurements

Anthropometric parameters were measured in a fasting state. The measurements were performed by a trained nutritionist. Body mass was measured to the nearest 0.1 kg with minimal clothing and without shoes using a digital Seca Beam Balance (Seca, Hamburg, Germany). Height was measured to the nearest 0.1 cm without footwear using a stadiometer in a standing position (Seca, Hamburg, Germany) Body composition was assessed by bioelectrical impedance analysis using the Tanita MC-780 S MA (Amsterdam, the Netherlands). Blood pressure was measured in a comfortable sitting position on the left arm using an aneroid sphygmomanometer and stethoscope after at least five-minutes rest on two occasions and the mean of the two was taken as the individual’s blood pressure.

REE measurements

Resting energy expenditure (REE), and maximum oxygen consumption (VO2 max) ml/min was measured by indirect calorimetry using the Fitmate Pro (Cosmed, Rome, Italy), which has good validity and reliability for assessment of REE in adults [56]. Energy expended during human performance can be measured by the volume of oxygen witch can consume while exercising at maximum capacity. VO2 max is the maximum rate of oxygen consumption.

Blood preparation for protein analysis

5 ml of whole blood was collected from all participants after 10–12 h of overnight fasting. 1 ml was transferred to a sterile microtube without any anticoagulant, centrifuged at 3000 RPM for 5 min, and the separated serum stored at − 70 °C until UCP2 was measured. The enzyme-linked immunosorbent assay (ELISA) method was applied to measure serum UCP2 protein by commercial kits (Shanghai Crystal Day Biotech Co., LTD, China) (Intra-assay Precision (Precision within an assay): CV% < 8%; Inter-assay Precision (Precision between assays): CV < 10).

Gene expression assessment

For measurement of gene expression, the remaining 4 ml of whole blood was used for the isolation of peripheral blood mononuclear cells (PBMCs) immediately after collection in tubes containing EDTA with anticoagulant (Vacutainer K2E). PBMCs were isolated by Ficoll Hypaque density-gradient centrifugation (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany). Total RNA purification was conducted by using the Ambion trizol reagent (Thermo Fisher Scientific), according to the manufacturer’s protocol. The quantity and quality of the RNA was assessed by using NanoDrop Spectrophotometry (NanoDrop OneC; Thermo Fisher Scientific). Then, complementary DNA (cDNA) synthesis was done according to the manufacturer’s protocol (ExcelRT One-Step RT-PCR Kit; smobio).

The integrity of the total RNA of the participants’ samples were assessed by gel electrophoresis (on a 1% agarose gel). For Real-time polymerase chain reaction, the PPARγ and UCP2 gene sequences were acquired from the National Center for Biotechnology Information (NCBI) and Ensembl ( databases. The OLIGO7 Software (Molecular Biology Insights, Inc., Cascade, CO) was used for designing the primer pairs PPARγ and UCP2 of mRNA sequence. Table 1 shows the PPARγ, UCP2, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequences of primers for the polymerase chain reaction. The level of PPARγ and UCP2 mRNA were examined using SYBR Green Master Mix (RealQ Plus 2x Master Mix Green, ampliqon, Denmark). The primer sequences for the human genes of PPARγ, UCP2, and GAPDH (as a housekeeping gene) were evaluated, and the data normalized to GAPDH mRNA expression by using the ΔΔCT comparative method. The fold changes of the PPARγ and UCP2 mRNA were calculated by using the REST Software as the relative expression of post-intervention/placebo [57].

Table 1 The sequences of PPARγ, UCP2, and GAPDH primers for polymerase chain reaction

Statistical analysis

The analyses were performed using STATA version 16 (StataCorp, College Station, TX, USA). Normality was checked by the Kolmogorov- Smirnov and Shapiro-Wilk test. Data were expressed as mean (SD) and frequency (percent) for categorical variables. Between-group comparisons of baseline measures and demographic variables were done by independent t-test, Mann-Whitney U test, and/or Chi-square test where appropriate. For within-group comparisons analysis of covariance (ANCOVA) and Wilcoxon sign-rank test were used, respectively, before and after intervention. In all analyses, P values less than 0.05 were considered as significant.


Of the 373 volunteers who were screened by phone, 46 met all inclusion/exclusion criteria. However, after a face to face meeting, 10 were excluded due to refusing to participate further. Therefore, a total of 36 participants completed the study (omega3 group n = 18; placebo group n = 18). The mean age of all participants was 21.86 (±3.15) years. The participants were athletes in at last one field (football n = 9, volleyball n = 3, basketball n = 4, athletics n = 2, archery n = 1, martial arts n = 6, swimming n = 4, weightlifting n = 3, wrestling n = 1, rock climbing n = 3). Table 2 shows the baseline demographic characteristics, blood pressure, and physical activity for intervention and placebo groups. There was no significant difference for any demographic parameter between groups. No adverse effects were reported by any of the participants at any stage of the study. Figure 1 shows the study flow diagram.

Table 2 Baseline characteristics of the study participants
Fig. 1
figure 1

Flow diagram

Effects of omega3 on the REE

As presented in Table 3, VO2 max, and REE were increased significantly in the omega3 group (p < 0.05). Also, REE was increased by 10.67% in the omega3 group (p < 0.001), and after baseline adjustments, the increase was 22.83% (p < 0.01).

Table 3 Comparison of the REE between study groups before and after the intervention

Effects of omega3 on appetite

Figure 2 presents VAS score at baseline and end of the study in omega3 and placebo groups. After three weeks of omega3 consumption, the sensation of hunger, desire to eat, desire to eat sweet taste, and desire to eat salty foods increased, but satiety and desire to eat fat decreased (p < 0.05).

Fig. 2
figure 2

VAS score at baseline and end of the study in omega3 and placebo group. Solid lines reveal intervention group, and dash lines demonstrate placebo group. VAS: Visual analogue scale

Effects of omega3 on the UCP2 levels in the blood

Table 4 compares the levels of UCP2 protein between study groups at baseline and the end of the intervention. The amount of UCP2 in blood was increased significantly in the intervention group (MD = 6.48 μg, p = 0.001), but decreased in the placebo group by 0.32 μg (p = 0.009). Compared to baseline levels, UCP2 increased by 7.17 μg (95% CI = 4.02, 12.85; P = 0.04).

Table 4 Comparison of the serum concentrations of UCP2 at before and after the intervention

Effects of omega 3 fatty acids on PPARγ and UCP2 gene expression

The Omega 3 and placebo groups had a significant difference in the fold change of PPARγ gene expression (p < 0.05). The mean (SE) fold change expression of UCP2 in comparison to GAPDH, in the Omega 3 group was 3.87 (0.31) and in the placebo group was 1.14 (0.14). Also, the Omega 3 and placebo groups also showed a significant difference in the fold change of PPARγ gene expression (p < 0.05). Mean (SE) fold change expression of in comparison to GAPDH, in the Omega 3 group was 3.37 (0.51), and in the placebo group was 1.30 (0.29). Figure 3 shows the difference between gene expressions of PPARγ and UCP2 in Omega 3 and Placebo groups.

Fig. 3
figure 3

Effect of 3 weeks omega3 supplementation on expression ratio. (p < 0.01 for both diagrams). a. Mean fold change of UCP2 expression in omega3 and placebo groups in comparison of GAPDH. b. Mean difference in fold change of PPARγ expression in omega3 and placebo groups in comparison of GAPDH. GAPDH: glyceraldehyde-3-phosphate dehydrogenase; UCP2: uncoupling protein2; PPARγ: peroxisome proliferator-activated receptor gamma


A large body of research has focused on PPARγ as a regulator of energy metabolism. On the other hand, many studies suggest that omega3 improves metabolism and homeostasis through the regulation of genes related to PPARγ signaling but the exact mechanisms were not known [29, 58]. Our results revealed that the level of PPARγ mRNA expression is significantly up-regulated in athletes who were administered omega3 supplements (p < 0.05). In line with our data, cell culture and animal studies demonstrate Omega 3 supplementation increased the expression of PPARγ [59,60,61]. Also, previous human studies showed in patients with obesity, diabetes mellitus, and gestational diabetes mellitus, omega3 supplementation unregulated gene expression of PPARγ [62,63,64]. A few studies showed omega3 had no significant effects on PPARγ mRNA levels in cultured cells, and even patients with diabetes mellitus [59, 65, 66] and one study indicated that twelve-weeks of omega3 supplementation in adolescents with obesity down-regulated PPARγ mRNA expression [58]. A lack of an effect of omega3 on PPARγ gene expression could be a consequence of a low expression of retinoid X receptor (RXR), as a heterodimer of PPARγ [60]. In light of these studies and our study, it seems that omega3, as a ligand of PPARγ, could up-regulate PPARγ mRNA expression. Further studies may be required to discover the exact molecular basis by which omega3 supplementation affects PPARγ expression.

By activating PPARγ, omega3 supplementation may enhance mitochondrial fatty acid oxidation [67]. One of the main promoters of oxidation in mitochondria are uncoupling proteins, especially UCP2 [42]. As presented in this study, after omega3 supplementation, UCP2 mRNA expression increased by 3.85 fold. Many cell culture and rodent studies show EPA or DHA increases UCP2 expression [68,69,70,71,72]. In agreement with our results, fish oil feeding can up-regulate mRNA of the UCP2 mRNA by five fold in mice [73]. Mice fed with omega3-containing food increased UCP2 mRNA in white adipose tissue 2.7 fold [72, 74]. Also, in mammals, UCP2 protein levels increase by the effect of omega3s [37]. In humans, two months of DHA-enriched food in football players increased UCP2 expression, although it was concluded that this enhancement might have been caused by oxidative stress due to exercise [75]. Another study showed eight weeks of DHA supplementation increased UCP2 protein levels after training [76]. In contrast to our study, two animal studies showed DHA and DHA-rich tuna oil did not affect UCP2 expression in rodents [77, 78] and an additional study demonstrated EPA suppressed overexpression of UCP2 in mice [79]. Another study found that after fish oil supplementation UCP2 was actually down-regulated [80]. The reason for these contrasting results could be due to different doses and duration of supplementation, the different conditions in cell cultures, and also the differences in the body components assessed across studies. In this regard, further studies are required to assess the different changes in UCP2 by omega3 supplementation in different health or disease conditions. Figure 4 shows the relation of omega 3 fatty acids, PPARγ and UCP2 in the terms of energy metabolism.

Fig. 4
figure 4

The relation of Omega 3 fatty acids, REE, PPARγ and UCP2. DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; PPARγ = Peroxisome proliferator-activated receptor-gamma; REE = Resting metabolic rate; UCP2 = Uncoupling protein2

As appetite is regulated by metabolic hormones and neurotransmitters, the genetic factors that affect metabolism (including PPARγ and subsequently UCP2 expression) could affect hunger sensation [43,44,45,46]. Barazzoni et al. (2004) showed appetite increased in rodents by increasing in PPARγ mRNA expression [81]. To our knowledge until now no study investigate this relationship in human. However, in our study increased PPARγ is related to increased appetite. Results across studies vary, however, as it has also been shown that increasing PPARγ expression suppresses ghrelin mRNA expression and thus reduces appetite and obesity [47, 48].

Appetite sensations are related to energy balance in the long term and can be affected by dietary factors such as omega3 fatty acids [82]. In our study, omega3 supplementation for three weeks increased hunger sensation (and desire to eat), and also decreased satiety. In agreement with these results, studies with similar duration (three weeks) demonstrated omega3 supplementation decreased satiety or increased hunger with 3.5 g omega3 or a combination of omega3 and omega6 in healthy individuals [49, 83]. However, in contrast to our study, weight loss program in individuals with overweight and obesity imply that omega3s may increase fullness, suppress appetite, or decrease hunger [84]. Differences in study populations, dose, and duration of intervention, physical activity, and nutrient intakes can be considered as reasons for conflicting results.

Our study showed an increase in resting energy expenditure with omega3 supplementation. UCP2 protein has been associated with resting energy expenditure, as subjects with obesity and low level of UCP2 protein have low resting energy expenditure [44]. In healthy humans, the effect of omega3s on REE (i.e. resting metabolic rate) is limited and controversial. In agreement with our study, some have reported REE increased by 5% after fish oil supplementation [85], while others reported no significant effect [86,87,88].

One study showed omega3 in the rat was associated with increased activity of the sodium-potassium pump ATPase, increased mitochondrial proton leak, and enhanced energy expenditure [89]. Omega3 binds to PPARγ, potentially altering the expression of proteins involved in fat metabolism. In general, it was suggested that supplementation with EPA and DHA may increase REE through enhanced fatty acid oxidation [90]. Some factors that may have contributed to the variable results in previous studies include low doses of omega3, shorter and variable supplementation periods, and small numbers of participants. Figure 4 shows the relation of omega 3 fatty acids, REE, PPARγ and UCP2.

A limitation of our study is the differential effects of EPA and DHA were not assessed. Another limitation is that as PPARγ is a nuclear receptor, it requires ligand for its activation and subsequent nuclear translocation. Compared to its expression levels, its protein level is very important, unfortunately this study could not measure it. The evaluation of expression levels of downstream target genes other than UCP2 is suggested for future research. Future studies should assess the effect of omega3 supplementation on fat distribution in the body, such as visceral or subcutaneous fat, and assess the effect of plant omega3s which are converted to DHA and EPA in the body. It is also recommended to evaluate the effect of very high doses and different durations of omega3s on altering the body composition. Also, we recommend the evaluation of the combination of omega3 with other obesity-related nutrients (especially vitamin D and E, Q10).


Omega 3 fatty acids may have an important role in affecting energy metabolism. Our findings showed that omega3 supplementation leads to the up-regulation of PPARγ and UCP2 expression in healthy athletes. These data provide additional evidence to support the hypothesis that these genes may act as a potential target for enhancing REE and appetite. Further investigations are suggested to confirm and support the recommendation of omega3s for weight reduction in patients with obesity-comorbidities.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.



Analysis of covariance


Body mass index


Blood pressure


Complementary DNA


Docosahexaenoic acid


Eicosapentaenoic acid


fat mass


fat free mass


global physical activity questionnaire


metabolic equivalent of task


Peroxisome proliferator-activated receptor-gamma


Peripheral blood mononuclear cell


Resting metabolic rate


Uncoupling protein2

VO2 max:

Maximal oxygen consumption


  1. McSwiney FT, Wardrop B, Hyde PN, Lafountain RA, Volek JS, Doyle L. Keto-adaptation enhances exercise performance and body composition responses to training in endurance athletes. Metabolism. 2018;81:25–34.

    Article  CAS  PubMed  Google Scholar 

  2. Jenner SL, et al. Dietary intake of professional Australian football athletes surrounding body composition assessment. J Int Soc Sports Nutr. 2018;15(1):1–8.

    Article  Google Scholar 

  3. Stellingwerff T. Case study: body composition periodization in an olympic-level female middle-distance runner over a 9-year career. Int J Sport Nutr Exerc Metab. 2018;28(4):428–33.

    Article  PubMed  Google Scholar 

  4. Devlin BL, et al. Dietary intake, body composition, and nutrition knowledge of Australian football and soccer players: implications for sports nutrition professionals in practice. Int J Sport Nutr. 2017;27(2):130–8.

    CAS  Google Scholar 

  5. Witard OC, Garthe I, Phillips SM. Dietary protein for training adaptation and body composition manipulation in track and field athletes. Int J Sport Nutr. 2019;29(2):165–74.

    CAS  Google Scholar 

  6. Miller T, et al. Resistance training combined with diet decreases body fat while preserving lean mass independent of resting metabolic rate: a randomized trial. Int J Sport Nutr. 2018;28(1):46–54.

    CAS  Google Scholar 

  7. Andersson-Hall U, Pettersson S, Edin F, Pedersen A, Malmodin D, Madsen K. Metabolism and whole-body fat oxidation following postexercise carbohydrate or protein intake. Int J Sport Nutr Exerc Metab. 2018;28(1):37–45.

    Article  CAS  PubMed  Google Scholar 

  8. Binia A, Vargas-Martínez C, Ancira-Moreno M, Gosoniu LM, Montoliu I, Gámez-Valdez E, et al. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARα L162V and PPARγ2 P12A. J Nutr Biochem. 2017;43:98–106.

    Article  CAS  PubMed  Google Scholar 

  9. Herbst E, et al. Omega-3 supplementation alters mitochondrial membrane composition and respiration kinetics in human skeletal muscle. J Physiol. 2014;592(6):1341–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Buckley JD, Howe P. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev. 2009;10(6):648–59.

    Article  CAS  PubMed  Google Scholar 

  11. Logan SL, Spriet LL. Omega-3 fatty acid supplementation for 12 weeks increases resting and exercise metabolic rate in healthy community-dwelling older females. PLoS One. 2015;10(12):e0144828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Saber A, Alipour B, Faghfoori Z, Yari Khosroushahi A. Secretion metabolites of dairy Kluyveromyces marxianus AS41 isolated AS probiotic, induces apoptosis in different human cancer cell lines and exhibit anti-pathogenic effects. J Funct Foods. 2017;34:408–21.

    Article  CAS  Google Scholar 

  13. Brown TJ, et al. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;366:l4697.

    Article  PubMed  PubMed Central  Google Scholar 

  14. NUTRITION, S. and C. TOXICITY, Advice on fish consumption: benefits & risks. Norwich: TSO (The Stationery Office); 2004.

    Google Scholar 

  15. Rabar S, Harker M, O'Flynn N, Wierzbicki AS, On behalf of the Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Bmj. 2014;349(jul17 12):g4356.

    Article  CAS  PubMed  Google Scholar 

  16. Krebs JD, Browning LM, McLean NK, Rothwell JL, Mishra GD, Moore CS, et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes. 2006;30(10):1535–44.

    Article  CAS  Google Scholar 

  17. Fearon K, von Meyenfeldt M, Moses AG, van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52(10):1479–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wu R-m, et al. Arctigenin enhances swimming endurance of sedentary rats partially by regulation of antioxidant pathways. Acta Pharmacologica Sinica. 2014;35(10):1274–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zand H, Rhimipour A, Bakhshayesh M, Shafiee M, Nour Mohammadi I, Salimi S. Involvement of PPAR-γ and p53 in DHA-induced apoptosis in Reh cells. Mol Cell Biochem. 2007;304(1–2):71–7.

    Article  CAS  PubMed  Google Scholar 

  20. Gladman SJ, Huang W, Lim SN, Dyall SC, Boddy S, Kang JX, et al. Improved outcome after peripheral nerve injury in mice with increased levels of endogenous omega-3 polyunsaturated fatty acids. J Neurosci. 2012;32(2):563–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Halcox JP. Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega–3 polyunsaturated fatty acid ethyl esters. Clin Lipidol. 2013;8(3):329–44.

    Article  CAS  Google Scholar 

  22. Virtanen JK. Dietary polyunsaturated fat intake in coronary heart disease risk: Taylor & Francis; 2015.

    Book  Google Scholar 

  23. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. Jama. 2012;308(10):1024–33.

    Article  CAS  PubMed  Google Scholar 

  24. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnane SC, et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr. 2009;139(4):804S–19S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Muskiet FA, et al. Is docosahexaenoic acid (DHA) essential? Lessons from DHA status regulation, our ancient diet, epidemiology and randomized controlled trials. J Nutr. 2004;134(1):183–6.

    Article  CAS  PubMed  Google Scholar 

  26. Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in cardiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6(3):216–34.

    Article  PubMed  Google Scholar 

  27. Rhodes D, et al. 2011–2012 What we eat in america, NHANES tables 1–40: Worldwide Web Site: Food Surveys Research Group 2014; 2014.

    Google Scholar 

  28. Nisoli E, Carruba MO, Tonello C, Macor C, Federspil G, Vettor R. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes. 2000;49(3):319–24.

    Article  CAS  PubMed  Google Scholar 

  29. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, et al. Adiponectin translation is increased by the PPARγ agonists pioglitazone and ω-3 fatty acids. Am J Physiol Endocrinol Metab. 2009;296(3):E480–9.

    Article  CAS  PubMed  Google Scholar 

  30. Tsai Y-S, Maeda N. PPARγ: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc Med. 2005;15(3):81–5.

    Article  CAS  PubMed  Google Scholar 

  31. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812(8):1007–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Siersbæk R, Nielsen R, Mandrup S. PPARγ in adipocyte differentiation and metabolism–novel insights from genome-wide studies. FEBS Lett. 2010;584(15):3242–9.

    Article  CAS  PubMed  Google Scholar 

  33. Walder K, Norman RA, Hanson RL, Schrauwen P, Neverova M, Jenkinson CP, et al. Association between uncoupling protein polymorphisms (UCP2–UCP3) and energy metabolism/obesity in Pima Indians. Hum Mol Genet. 1998;7(9):1431–5.

    Article  CAS  PubMed  Google Scholar 

  34. Salopuro T, Pulkkinen L, Lindström J, Kolehmainen M, Tolppanen AM, Eriksson JG, et al. Variation in the UCP2 and UCP3genes associates with abdominal obesity and serum lipids: the Finnish diabetes prevention study. BMC Med Genet. 2009;10(1):94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dhamrait SS, et al. Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J Acute Cardiovasc Care. 2004;25(6):468–75.

    CAS  Google Scholar 

  36. de Oliveira BAP, de Souza Pinhel MA, Nicoletti CF, de Oliveira CC, Quinhoneiro DCG, Noronha NY, et al. UCP2 and PLIN1 expression affects the resting metabolic rate and weight loss on obese patients. Obes Surg. 2017;27(2):343–8.

    Article  PubMed  Google Scholar 

  37. Perez R, Cañón J, Dunner S. Genes associated with long-chain omega-3 fatty acids in bovine skeletal muscle. J Appl Genet. 2010;51(4):479–87.

    Article  CAS  PubMed  Google Scholar 

  38. Marta F, et al. Omega-3 fatty acids as regulators of brown/beige adipose tissue: from mechanisms to therapeutic potential. J Physiol Pharmacol. 2020;76(2):251–67.

    Google Scholar 

  39. Rad EY, et al. Omega-3 fatty acids and vitamin E supplementation can affect gene expressions of SIRT1, FOXO1 and UCP-2 in coronary artery disease patients. Obes Med. 2019;15:100116.

    Article  Google Scholar 

  40. Mohammadi M, Abbasalipourkabir R, Ziamajidi N. Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways. Arch Physiol Biochem. 2020:1–9.

  41. Wang P, Li B, Cai G, Huang M, Jiang L, Pu J, et al. Activation of PPAR-γ by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2. J Cardiovasc Pharmacol. 2014;64(6):497–506.

    Article  CAS  PubMed  Google Scholar 

  42. Villarroya F, Iglesias R, Giralt M. PPARs in the control of uncoupling proteins gene expression. PPAR Res. 2007;2007:1–12.

    Article  Google Scholar 

  43. Parker HM, Cohn JS, O'Connor HT, Garg ML, Caterson ID, George J, Johnson NA. Effect of fish oil supplementation on hepatic and visceral fat in overweight men: a randomized controlled trial. Nutrients. 2019;11(2):475.

  44. Taghadomi Masoumi Z, Eshraghian MR, Hedayati M, Pishva H. Association between uncoupling protein 2, adiponectin and resting energy expenditure in obese women with normal and low resting energy expenditure. Gynecol Endocrinol. 2018;34(2):166–70.

    Article  CAS  PubMed  Google Scholar 

  45. Zarebska A, Jastrzebski Z, Cieszczyk P, Leonska-Duniec A, Kotarska K, Kaczmarczyk M, et al. The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene modifies the association of physical activity and body mass changes in polish women. PPAR Res. 2014;2014:1–7.

    Article  Google Scholar 

  46. MF, AZ. The function of uncoupling proteins in various tissues. Majallahi Danishkadahi Pizishkii Isfahan. 2013;31(241):903–22.

    Google Scholar 

  47. Li Q, Yu Q, Lin L, Zhang H, Peng M, Jing C, et al. Hypothalamic peroxisome proliferator-activated receptor gamma regulates ghrelin production and food intake. Neuropeptides. 2018;69:39–45.

    Article  CAS  PubMed  Google Scholar 

  48. Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, Friedman JM, et al. UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature. 2008;454(7206):846–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Damsbo Svendsen S, Rønsholdt MD, Lauritzen L. Fish oil-supplementation increases appetite in healthy adults. A randomized controlled cross-over trial. Appetite. 2013;66:62–6.

    Article  PubMed  Google Scholar 

  50. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes. 2000;24(1):38–48.

    Article  CAS  Google Scholar 

  51. Péter S, Navis G, de Borst MH, von Schacky C, van Orten-Luiten ACB, Zhernakova A, et al. Public health relevance of drug–nutrition interactions. Eur J Nutr. 2017;56(2):23–36.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Agostoni C, Bresson JL, Tait SF, Flynn A, Golly I, Korhonen H, Lagiou P, et al. Scientific opinion on the tolerable Upper Intake Level of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA) and Docosapentaenoic Acid (DPA): EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). 2012.p. 1–48.

  53. Huang W, Fan Q, Zhang X. Cod liver oil: a potential protective supplement for human glaucoma. Int J Ophthalmol. 2011;4(6):648–51.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Armstrong T, Bull F. Development of the world health organization global physical activity questionnaire (GPAQ). J Public Health. 2006;14(2):66–70.

    Article  Google Scholar 

  55. BashiriMoosavi F, et al. Level of physical activity among girl high school students in Tarom county and relevant factors. Iran J Health Educ Health Promotion. 2015;3(2):133–40.

    Google Scholar 

  56. Nieman DC, Austin MD, Benezra L, Pearce S, McInnis T, Unick J, et al. Validation of Cosmed’s FitMate™ in measuring oxygen consumption and estimating resting metabolic rate. Res Sports Med. 2006;14(2):89–96.

    Article  PubMed  Google Scholar 

  57. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Mejía Barradas CM, et al. The consumption of n-3 polyunsaturated fatty acids differentially modulates gene expression of peroxisome proliferator-activated receptor alpha and gamma and hypoxia-inducible factor 1 alpha in subcutaneous adipose tissue of obese adolescents. Endocrine. 2014;45(1):98–105.

    Article  CAS  PubMed  Google Scholar 

  59. Tian C, Fan C, Liu X, Xu F, Qi K. Brain histological changes in young mice submitted to diets with different ratios of n-6/n-3 polyunsaturated fatty acids during maternal pregnancy and lactation. Clin Nutr. 2011;30(5):659–67.

    Article  CAS  PubMed  Google Scholar 

  60. Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor γ. Obes Res. 2002;10(6):518–25.

    Article  CAS  PubMed  Google Scholar 

  61. Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-γ–dependent mechanism. Kidney Int. 2005;67(3):867–74.

    Article  CAS  PubMed  Google Scholar 

  62. Mansoori A, Sotoudeh G, Djalali M, Eshraghian MR, Keramatipour M, Nasli-Esfahani E, et al. Effect of DHA-rich fish oil on PPARγ target genes related to lipid metabolism in type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Lipidol. 2015;9(6):770–7.

    Article  PubMed  Google Scholar 

  63. Jamilian M, Tabassi Z, Reiner Ž, Panahandeh I, Naderi F, Aghadavod E, et al. The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2020;123(7):792–9.

    Article  CAS  PubMed  Google Scholar 

  64. Martínez-Fernández L, et al. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostag Oth Lipid M. 2015;121:24–41.

    Google Scholar 

  65. Mansoori A, et al. Docosahexaenoic acid-rich fish oil supplementation improves body composition without influence of the PPARγ Pro12Ala polymorphism in patients with yype 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Lifestyle Genom. 2015;8(4–6):195–204.

    CAS  Google Scholar 

  66. MacLaren LA, Guzeloglu A, Michel F, Thatcher WW. Peroxisome proliferator-activated receptor (PPAR) expression in cultured bovine endometrial cells and response to omega-3 fatty acid, growth hormone and agonist stimulation in relation to series 2 prostaglandin production. Domest Anim. 2006;30(3):155–69.

    Article  CAS  Google Scholar 

  67. Anderson EJ, Thayne KA, Harris M, Shaikh SR, Darden TM, Lark DS, Williams JM, Chitwood R, Kypson AP, Rodriguez E. "Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARγ activation?." 2014. p. 1156–63.

  68. Hsu H, Chen C, Chen M. N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes--involvement of uncoupling protein UCP2. J Biomed Sci. 2014;21(1):1–11.

    Article  CAS  Google Scholar 

  69. Casanova E, Baselga-Escudero L, Ribas-Latre A, Arola-Arnal A, Bladé C, Arola L, et al. Epigallocatechin gallate counteracts oxidative stress in docosahexaenoxic acid-treated myocytes. Biochim Biophys Acta. 2014;1837(6):783–91.

    Article  CAS  PubMed  Google Scholar 

  70. Wu Y, Zhang C, Dong Y, Wang S, Song P, Viollet B, et al. Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20: 5 n-3) improves endothelial function in vivo. PLoS One. 2012;7(4):e35508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Armstrong MB, Towle HC. Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARα-mediated pathway. Am J Physiol Endocrinol Metab. 2001;281(6):E1197–204.

    Article  CAS  PubMed  Google Scholar 

  72. Hun CS, Hasegawa K, Kawabata T, Kato M, Shimokawa T, Kagawa Y. Increased uncoupling protein2 mRNA in white adipose tissue, and decrease in leptin, visceral fat, blood glucose, and cholesterol in KK-ay mice fed with eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid. Biochem Biophys Res Commun. 1999;259(1):85–90.

    Article  CAS  PubMed  Google Scholar 

  73. Tsuboyama Kasaoka N, et al. Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice. Biochem Biophys Res Commun. 1999;257(3):879–85.

    Article  CAS  PubMed  Google Scholar 

  74. Addison O, Marcus RL, LaStayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol. 2014;2014:1–11.

    Article  CAS  Google Scholar 

  75. Capó X, Martorell M, Sureda A, Llompart I, Tur JA, Pons A. Diet supplementation with DHA-enriched food in football players during training season enhances the mitochondrial antioxidant capabilities in blood mononuclear cells. Eur J Nutr. 2015;54(1):35–49.

    Article  CAS  PubMed  Google Scholar 

  76. Busquets-Cortés C, Capó X, Martorell M, Tur JA, Sureda A, Pons A. Training enhances immune cells mitochondrial biosynthesis, fission, fusion, and their antioxidant capabilities synergistically with dietary docosahexaenoic supplementation. Oxid Med Cell Longev. 2016. p. 8950384.

  77. MFD, et al. The Effect of docosahexaenoic acid on t 10, c 12-conjugated linoleic acid-induced changes in fatty acid composition of mouse liver, Adipose, and Muscle. Metab Syndr Relat Disord. 2013;11(1):63–70.

    Article  Google Scholar 

  78. Arai T, Kim HJ, Chiba H, Matsumoto A. Interaction of fenofibrate and fish oil in relation to lipid metabolism in mice. J Atheroscler Thromb. 2009;16(3):283–91.

    Article  CAS  PubMed  Google Scholar 

  79. Kato T, Shimano H, Yamamoto T, Ishikawa M, Kumadaki S, Matsuzaka T, et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes. 2008;57(9):2382–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Ferreira M, Chicco A, Lombardo Y. Dietary fish oil normalized glucose-stimulated insulin secretion in isolated pancreatic islets of dyslipemic rats through mechanisms involving glucose phosphorylation, peroxisome proliferator-activated receptor γ and uncoupling protein 2. Prostaglandins Leukot Essent. 2013;89(1):31–8.

    Article  CAS  Google Scholar 

  81. Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288(1):E228–35.

    Article  CAS  PubMed  Google Scholar 

  82. Huang C, et al. Influence of dietary alpha-lipoic acid and lipid level on the growth performance, food intake and gene expression of peripheral appetite regulating factors in juvenile grass carp (Ctenopharyngodon idellus). Aquac Res. 2019;505:412–22.

    Article  CAS  Google Scholar 

  83. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids and the brain: from infancy to aging. Neurobiol. Aging. 2005;26 Suppl 1:98–102.

    Article  CAS  PubMed  Google Scholar 

  84. Parra D, Ramel A, Bandarra N, Kiely M, Martínez JA, Thorsdottir I. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite. 2008;51(3):676–80.

    Article  CAS  PubMed  Google Scholar 

  85. Gerling CJ, Whitfield J, Mukai K, Spriet LL. Variable effects of 12 weeks of omega-3 supplementation on resting skeletal muscle metabolism. Appl Physiol Nutr Metab. 2014;39(9):1083–91.

    Article  CAS  PubMed  Google Scholar 

  86. Bortolotti M, Tappy L, Schneiter P. Fish oil supplementation does not alter energy efficiency in healthy males. Clin Nutr. 2007;26(2):225–30.

    Article  CAS  PubMed  Google Scholar 

  87. Noreen EE, et al. Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults. J Int Soc Sports Nutr. 2010;7(1):1–7.

    Article  Google Scholar 

  88. Jannas-Vela S, Roke K, Boville S, Mutch DM, Spriet LL. Lack of effects of fish oil supplementation for 12 weeks on resting metabolic rate and substrate oxidation in healthy young men: a randomized controlled trial. PLoS One. 2017;12(2):e0172576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Hulbert AJ. Membrane fatty acids as pacemakers of animal metabolism. Lipids. 2007;42(9):811–9.

    Article  CAS  PubMed  Google Scholar 

  90. Nagahuedi S, Popesku JT, Trudeau VL, Weber JM. Mimicking the natural doping of migrant sandpipers in sedentary quails: effects of dietary n-3 fatty acids on muscle membranes and PPAR expression. J Exp Biol. 2009;212(8):1106–14.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to thank the people who participated in this study. The results of this article are derived from the Ph.D. thesis of Sara Moradi (63564).


No funding was received.

Author information

Authors and Affiliations



S M, B A, M A, M AJ, and Y KH designed the study; SM and MA collect the data; S M and M AJ analyzed the data; S M drafted the report; S M, P D. C, and Y KH worked on the completion of the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Beitullah Alipour.

Ethics declarations

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the Tabriz University Medical of Sciences (IR.TBZMED.REC.1398.782) in October 2019. All procedures were performed in accordance with relevant guidelines. Informed consent obtained from all the participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moradi, S., Alivand, M., KhajeBishak, Y. et al. The effect of omega3 fatty acid supplementation on PPARγ and UCP2 expressions, resting energy expenditure, and appetite in athletes. BMC Sports Sci Med Rehabil 13, 48 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: